Company / Cost of Revenue
Sonoma Pharmaceuticals, Inc. Cost of Revenue History
FY2017-FY2026 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$8.8M
FY2026
5-year range
$8.0M / $12.1M
FY2022-FY2026
Trend
+10.4%
vs FY2025
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has fluctuated over the past 10 years, ranging from $7M in FY2017 to $12M in FY2022.
Based on SEC 10-K filings.
$9M in FY2026 with a 5-year CAGR of -2.1%.
Remained stable around $9M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +0.7%
- 5-Year CAGR
- -2.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -2.1%, indicating a declining trend.
- In FY2026, cost of revenue increased 10.4% year-over-year.
- Peak cost of revenue was recorded in FY2022.
- Lowest cost of revenue in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | $8.8M | +10.4% |
| FY2025 | $8.0M | -9.2% |
| FY2024 | $8.8M | +1.9% |
| FY2023 | $8.6M | -28.5% |
| FY2022 | $12.1M | +23.1% |
| FY2021 | $9.8M | -2.8% |
| FY2020 | $10.1M | +7.9% |
| FY2019 | $9.3M | +30.6% |
| FY2018 | $7.2M | +6.5% |
| FY2017 | $6.7M | +2.4% |
As of FY2026 · SEC 10-K · Updated Jun 28, 2026